Anti-Aging & Longevity / side effects and safety / Last reviewed 2026-04-04

SS-31 Side Effects: Safety Signals and Warnings

SS-31 safety concerns are compound-specific. The main listed side effects are Injection site reactions, Headache, and Mild gastrointestinal symptoms. The main warning signals are Still in clinical trials, not yet FDA-approved, Long-term safety profile not fully established, and Some clinical trials have shown mixed results.

Read the full SS-31 guide Browse answer pages

Direct Answer

Evidence for SS-31 (elamipretide) is too preliminary to support a research protocol with confidence. Despite promising mitochondrial mechanistic data and early trials, Phase 3 results for Barth syndrome and heart failure have been mixed or failed to meet primary endpoints. Of the Anti-Aging & Longevity compounds, NAD+ precursors and carnosine have better-established human evidence profiles.

Evidence grade
Level B
Research status
Phase 3
Category
Anti-Aging & Longevity
Best for
Mitochondrial dysfunction research, cardioprotection, oxidative stress

Reported Side Effects

Warnings

Known or Plausible Interactions

Regulatory Context

Investigational drug in Phase 3 clinical trials. Not yet FDA-approved. Fast Track designation from FDA for Barth syndrome. Orphan drug designation for several rare mitochondrial conditions. Not available as a research peptide in most markets.

Evidence Snapshot

Evidence gradeLevel B
Research statusPhase 3
Best supported outcomesMitochondrial Function (Level B), Heart Failure (Level B), Exercise Capacity (Level B), and Kidney Protection (Level C)
Primary citation count3
Last reviewed2026-04-04

Related Guides

How to Cite This Page

ExaminePeptides. "SS-31 Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/ss-31-side-effects-safety/

This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.